We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

105 hedge funds and large institutions have $328M invested in UroGen Pharma in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 18 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 18

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

32% more capital invested

Capital invested by funds: $248M → $328M (+$79.7M)

12.29% more ownership

Funds ownership: 58.53% → 70.82% (+12%)

4% more funds holding

Funds holding: 101 → 105 (+4)

2% more call options, than puts

Call options by funds: $344K | Put options by funds: $336K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
105
Holders Change
+4
Holders Change %
+3.96%
% of All Funds
1.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
16
Increased
50
Reduced
18
Closed
12
Calls
$344K
Puts
$336K
Net Calls
+$8K
Net Calls Change
-$525K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$20.8M
2
RI
RTW Investments
New York
+$11.3M
3
Morgan Stanley
Morgan Stanley
New York
+$10.4M
4
BlackRock
BlackRock
New York
+$6.77M
5
Millennium Management
Millennium Management
New York
+$1.96M

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$5.21M
2
CI
Clal Insurance
Israel
-$3.11M
3
EI
EAM Investors
California
-$2.39M
4
LCM
Laurion Capital Management
New York
-$1.69M
5
CSS
Cubist Systematic Strategies
Connecticut
-$1.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
51
Walleye Capital
New York
$408K +$353K +27,218 New
Susquehanna International Group
52
Susquehanna International Group
Pennsylvania
$401K +$85.1K +6,553 +32%
BP
53
BBR Partners
New York
$390K – – –
UBS Group
54
UBS Group
Switzerland
$376K +$75.9K +5,850 +30%
PAI
55
Palo Alto Investors
California
$368K – – –
JP Morgan Chase
56
JP Morgan Chase
New York
$359K +$63.6K +4,901 +26%
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$345K +$85.9K +6,617 +40%
KHLMTHM
58
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet
Israel
$327K – – –
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$309K +$46.8K +3,607 +21%
VCM
60
Vivaldi Capital Management
Illinois
$309K – – –
Citigroup
61
Citigroup
New York
$280K +$237K +18,278 +4,502%
AQR Capital Management
62
AQR Capital Management
Connecticut
$276K +$239K +18,383 New
Two Sigma Advisers
63
Two Sigma Advisers
New York
$275K -$7.79K -600 -3%
CAM
64
Cresset Asset Management
Illinois
$251K – – –
Jane Street
65
Jane Street
New York
$249K +$85.1K +6,552 +65%
PCIG
66
Partners Capital Investment Group
Massachusetts
$231K – – –
MIM
67
MetLife Investment Management
New Jersey
$219K +$54.8K +4,223 +41%
SSA
68
Sierra Summit Advisors
Nevada
$218K +$188K +14,515 New
EGM
69
Engineers Gate Manager
New York
$204K +$177K +13,610 New
AIG
70
American International Group
New York
$203K +$48.8K +3,756 +38%
Federated Hermes
71
Federated Hermes
Pennsylvania
$176K -$18.4K -1,421 -11%
Mirae Asset Global Investments
72
Mirae Asset Global Investments
South Korea
$170K +$779 +60 +0.5%
VOYA Investment Management
73
VOYA Investment Management
Georgia
$166K +$144K +11,080 New
Manulife (Manufacturers Life Insurance)
74
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$161K +$139K +10,716 New
EFG
75
Ethos Financial Group
Pennsylvania
$158K – – –
1 2
3
4 5

URGN Hedge Fund Activity: Q4 2023 in Review

105 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2023, worth a combined $328M — up 32% from $248M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new URGN positions and 12 closed out — a net gain of 4 holders — while 50 added to existing stakes and 18 trimmed.

The largest buyer was RA Capital Management, adding an estimated $20.8M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $5.21M sold.

  • 105 institutional investors held UroGen Pharma (URGN) as of Q4 2023, up from 101 in Q3 2023.
  • Funds reported $328M of UroGen Pharma stock for Q4 2023, up 32% quarter-over-quarter.
  • 16 funds opened new UroGen Pharma positions in Q4 2023 and 12 closed out, a net change of +4 holders.
  • The largest UroGen Pharma buyer in Q4 2023 was RA Capital Management, an estimated $20.8M added.
  • The largest UroGen Pharma seller in Q4 2023 was Soleus Capital Management, an estimated $5.21M sold.

Based on aggregated 13F filings for Q4 2023.